Hetlioz prescription volume trends and market penetration in Non-24 and Smith-Magenis Syndrome patient populations
Clinical trial readouts for pipeline candidates or label expansion studies
FDA regulatory decisions on new drug applications or supplemental approvals
Reimbursement coverage decisions from major payers affecting product access
low - Specialty pharmaceuticals for rare diseases and chronic psychiatric conditions exhibit minimal correlation to GDP or economic cycles. Patients with Non-24 disorder or schizophrenia require continuous treatment regardless of economic conditions. However, commercial insurance coverage and patient affordability programs may face pressure during recessions, potentially affecting prescription fulfillment rates.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting biotech stocks trading on future earnings potential rather than current cash flows. (2) Cash investments generate higher yields, partially offsetting operating losses, but this benefit is minor relative to valuation compression. The company's minimal debt (0.05 D/E) eliminates refinancing risk.
Orphan drug market size limitations - Non-24 disorder affects estimated 80,000-140,000 totally blind individuals in the US, creating a natural revenue ceiling that may not support current cost structure
Regulatory pathway complexity for CNS drugs requiring long-term safety data and potential FDA scrutiny on efficacy endpoints
Reimbursement environment for high-cost specialty drugs facing increasing payer pushback and prior authorization requirements
growth/speculative - The stock attracts investors focused on turnaround potential and pipeline optionality rather than current profitability. Negative margins and cash flow eliminate value and dividend investors. The 35% one-year return suggests momentum traders have participated. Typical holders include biotech-focused funds, special situations investors betting on commercial inflection, and retail investors attracted to small-cap healthcare volatility. The low market cap ($400M) and negative earnings create significant volatility and limit institutional ownership.
No analyst coverage available for this stock.
Trend
-4.5% vs SMA 50 · +28.6% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
VNDA News
Unable to load news
About
vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
VNDA◀ | $7.37 | -1.41% | $414M | — | +872.0% | -10202.2% | 1500 |
| $68.91 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $520.84 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $88.52 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $181.75 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $228.45 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $75.32 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.78% | — | 40.5 | +342033.3% | -4883.3% | 1500 |